CircRNA_0079586 and circRNA_RanGAP1 are involved in the pathogenesis of intracranial aneurysms rupture by regulating the expression of MPO

Zhuang Zhang¹, Rubo Sui¹, Lili Ge² & Dongjian Xia³

Several circRNAs have been reported to be dysregulated in human endothelial cells through sponging miRNAs. Previous reports demonstrated that MPO not only contributed to the formation and rupture of cerebral aneurysm but was also correlated with the degenerative remodeling predisposition to saccular intracranial aneurysm wall rupture, although its underlying mechanisms remain to be explored. Microarray screening was performed to compare the differential expression of circRNAs in the endothelial cells collected from UIAs and RIAs patients. Luciferase assays were used to explore the regulatory relationship between circRNAs and miRNAs, and between miRNAs and their target genes. Microarray screening analysis found a batch of up-regulated circRNAs in the endothelial cells harvested from RIAs patients, including circRNA-0079586 and circRNA-RanGAP1. Luciferase assays revealed the suppressive role of miR-183-5p/miR-877-3p in the expression of circRNA-0079586/ circRNA-RanGAP1/MPO. And the expression of circRNA-0079586 and circRNA-RanGAP1 was respectively suppressed by the overexpression of miR-183-5p and miR-877-3p. And both the transfection of miR-183-5p and miR-877-3p mimics suppressed the relative expression level of MPO mRNA. The expression of circRNA-0079586, circRNA-RanGAP1 and MPO was significantly activated in the endothelial cells collected from RIAs patients when compared with UIAs patients, whereas the expression of miR-183-5p and miR-877-3p was remarkably suppressed in the endothelial cells collected from RIAs patients when compared with UIAs patients. We further altered the expression of circRNA-0079586 and circRNA-RanGAP1 using siRNA and overexpression in HUVECs, and the expression of circRNA-0079586 and circRNA-RanGAP1 was significantly and negatively correlated with the expression of miR-183-5p and miR-877-3p, but positively correlated with the expression of MPO under different conditions. In this study, we established two MPO-modulating signaling pathways of circRNA_0079586/miR-183-5p/MPO and circRNA_RanGAP1/miR-877-3p/MPO. These two signaling pathways are involved in the pathogenesis of intracranial aneurysms rupture.

Abbreviations

HUVECs  Human umbilical endothelial cells
IA  Intracranial aneurysm
RIAs  Ruptured intracranial aneurysms
UIAs  Unruptured intracranial aneurysms
WSS  Wall shear stress
TF  Turbulent flow

Intracranial aneurysm (IA) rupture is an extensively examined topic. Also, unruptured IA is reported in 5% of adults globally¹⁻⁵. Although the rate of ruptured IA is actually not high, ruptured IA can lead to significant

¹Department of Neurology, The First Affiliated Hospital, Jinzhou Medical University, Jinzhou, China. ²Department of Ultrasound, The First Affiliated Hospital, Jinzhou Medical University, Jinzhou, China. ³Department of Neurosurgery, The First Affiliated Hospital, Jinzhou Medical University, Renmin Street, No.2, Fifth Duan, Jinzhou, China. *email: conditionnerve@163.com
informed consent was obtained from all patients before the study. All methods were performed in accordance with the last vision of the Declaration of Helsinki. Written Research Ethics Committees of the First Affiliated Hospital of Jinzhou Medical University has approved this study. In this study, we aimed to study the molecular mechanism underlying the role of MPO and its potential signaling pathways.

Circular RNAs (circRNAs) belong to a subfamily of endogenous non-coding RNAs (ncRNAs) and are mainly consisted of exonic transcripts produced via back splicing. Different from linear RNAs, circRNA is a covalently closed continuous loop without 5′–3′ polarity or a polyadenylated tail which commonly originates from protein-coding genes and complete exons. And it was reported that eukaryotic circRNAs are mainly produced during splicing, catalyzed by spliceosomal machinery or by groups I and II ribozymes. Moreover, circRNA is also known as miRNA sponge, which regulates the expression of miRNAs. Recent research has actually shown that circRNAs are richly expressed in cells to serve as a necessary regulator in transcriptional as well as post-transcriptional gene expression. In colon cancer patients, circRNA CDR1as is significantly overexpressed in tumor tissues, while the silencing of CDR1as hinders the development of tumors by targeting miRNA-720. In a previous report, it was failed to show that MPO is linked to the clinical risk of IA rupture. Therefore, it was proposed that the presence of MPO might indicate a more delicate wall of aneurysm that is prone to IA rupture. The level of MPO can be identified using enhanced MRI or blood samples collected from IA fundus. It was also suggested that MPO might be used as a biomarker to examine the risk of IA rupture. Also, the measurement of MPO might improve the assessment of cardiovascular diseases. Moreover, it was suggested that myeloperoxidase (MPO) played a key role in inflammation as well as oxidative stress, and is involved in the onset and development of atherosclerosis. And circRNAs have been reported to take key regulatory roles in pathological biological processes such as inflammation and cell proliferation. Besides, miR-183-5p was demonstrated to suppress inflammatory responses in intracerebral hemorrhage mice, while miR-887-3p was found to lead to dysregulated inflammation and enhance lung injury by increasing the cytokine production in ICU patients with severe sepsis.

Several circRNAs have been reported to be dysregulated in human endothelial cells. Specially, circRNA_0079586 was found to accelerate the progression of glioma via interacting with miR-183-5p, while circRNA_RanGAP1 was found to facilitate gastric cancer invasion and metastasis via interacting with miR-877-3p. Moreover, previous reports demonstrated that MPO not only contributed to the formation and rupture of cerebral aneurysm, but was also correlated with the degenerative remodeling predisposition to saccular intracranial aneurysm wall rupture. In this study, we aimed to study the molecular mechanism underlying the role of MPO and its potential signaling pathways.

Materials and methods

Human subjects sample collection. In this study, we recruited 34 IA patients and divided them into two groups based on their status of IA: RIA (ruptured intracranial aneurysms, N = 18) and UIA (unruptured intracranial aneurysms, N = 16). Intracranial aneurysm tissue samples were collected after removal surgery from patients in both groups following previous published methods. Endothelial cells were isolated from surgically removed intracranial aneurysm. The clinical features including sex, age, hypertension, smoking history, lesion size were collected from the patients in the two groups and compared using Student’s t tests. The Human Research Ethics Committees of the First Affiliated Hospital of Jinzhou Medical University has approved this research. All methods were performed in accordance with the last vision of the Declaration of Helsinki. Written informed consent was obtained from all patients before the study.

Primary culture of endothelial cells from human carotid artery. EC primary culture (Cell applications, San Diego, CA) was derived from human carotid arteries, and the characteristics of the EC primary culture were confirmed by immunohistochemistry.

Loading shear stress. To measure the loading shear stress, the primary ECs were cultured on glass slides coated with gelatin overnight and then loaded with a shear stress of 0.05 and 3.0 Pa. After 24 h of culturing under the loaded shear stress, the primary ECs were harvested for other analyses. Additionally, the primary ECs were also subjected to the treatment with a turbulent flow as previously described.

Genotyping by direct sequencing. Total RNA of the samples was first extracted by using a Trizol reagent (Invitrogen, Carlsbad, CA) according to the directions of the reagent manufacturer. Then, the extracted total RNA was subsequently processed using DNase I (Takara, Dalian, China) according to the directions of the reagent manufacturer to get rid of genomic DNA contaminants. In the next step, equal volumes of total RNA extracted from each sample were subject to deep sequencing, which was carried out by BGI (Shenzhen, China) by making use of an Illumina Solexa platform.
Microarray analysis. To examine the circRNA expression profile in collected tissue and cell samples, the total RNA, which also contained circRNAs and miRNAs, in each sample was isolated and studied using the Affymetrix GeneChip miRNA 2.0 microarray (Affymetrix, Santa Clara, CA) according to the directions of the microarray manufacturer. Based on the results, circRNAs identified with changed expression were divided into 2 groups, i.e., a group of circRNAs with upregulated expression and a group of circRNAs with downregulated expression. The group of circRNAs with upregulated expression included 9 circRNAs: circRNA_0004543 (2.6-fold increase in expression), circRNA_0079586 (4.1-fold increase in expression), circRNA_0000231 (3.5-fold increase in expression), circRNA_0091822 (3.5-fold increase in expression), circRNA_RanGAP1 (3.9-fold increase in expression), circRNA_943034 (3.1-fold increase in expression), and circRNA_320434 (1.9-fold increase in expression). The group of circRNAs with downregulated expression included 6 circRNAs: circRNA_0030492 (2.1-fold decrease in expression), circRNA_0011032 (2.5-fold decrease in expression), circRNA_0004264 (3.2-fold decrease in expression), circRNA_0002331 (3.7-fold decrease in expression), circRNA_0004528 (2.8-fold decrease in expression), and circRNA_0000345 (2.6-fold decrease in expression).

RNA isolation and real-time PCR. RNA isolation and real-time PCR were carried out to study the expression of circRNA_0079586, circRNA_RanGAP1, miR-183-5p, miR-877-3p, and MPO mRNA in each sample. In brief, total RNA in each sample was extracted using a mirVana RNA extraction assay kit (Ambion, San Diego, CA) according to the directions of the assay kit manufacturer. Then, the integrity and content of extracted RNA was evaluated by using an Agilent 2100 BioAnalyzer (Agilent, San Jose, CA) according to the directions of the instrument manufacturer. In the next step, an NCode VILO cDNA synthesis assay kit (Qiagen, Germantown, MD) was used according to the directions of the assay kit manufacturer to create cDNA templates for real time quantitative PCR analysis, which was performed by using a Quantifast SYBR Green master mix (Qiagen, Germantown, MD) according to the directions of the assay kit manufacturer to calculate the relative expression of circRNA_0079586, circRNA_RanGAP1, miR-183-5p, miR-877-3p, and MPO mRNA in each sample using the 2−ΔΔCT approach. The real time quantitative PCR was carried out on a LightCycler 480 equipment (Roche, Basel, Switzerland) according to the directions of the equipment manufacturer.

Cell culture and transfection. HUVEC cells were acquired from ATCC and cultured in a Dulbecco’s modified Eagle's medium (DMEM, Gibco, Thermo Fisher Scientific, Waltham, MA) containing 4.5 g/l of glucose, 10% fetal bovine serum as well as streptomycin and streptomycin (Sigma Aldrich, St. Louis, MO). The culture was done in a 37°C humidified environment of 5% carbon dioxide and 95% air. When HUVEC cells were confluent, they were used to establish 5 cellular models as below. In cellular model I, HUVEC cells were divided into 5 groups, i.e., 1. WSS group (HUVEC cells subjected to WSS stress loading and treated with PBS); 2. TF group (HUVEC cells subjected to TF treatment); 3. TF + NC siRNA group (HUVEC cells subjected to TF treatment and then transfected with NC siRNA); 4. TF + circRNA_0079586 siRNA group (HUVEC cells subjected to TF treatment and then transfected with siRNA targeting circRNA_0079586); and 5. TF + circRNA_RanGAP1 siRNA group (HUVEC cells subjected to TF treatment and then transfected with siRNA targeting circRNA_RanGAP1). In cellular model II, HUVEC cells were divided into 4 groups, i.e., 1. NC group (HUVEC cells transfected with NC plasmid); 2. p-circRNA_0079586 group (HUVEC cells transfected with p-circRNA_0079586 plasmid); 3. p-circRNA_RanGAP1 group (HUVEC cells transfected with p-circRNA_RanGAP1 plasmid); and 4. p-circRNA_0079586 + p-circRNA_RanGAP1 group (HUVEC cells transfected with both p-circRNA_0079586 and p-circRNA_RanGAP1 plasmids). In cellular model III, HUVEC cells were divided into 4 groups, i.e., 1. NC siRNA group (HUVEC cells transfected with NC siRNA); 2. circRNA_0079586 siRNA group (HUVEC cells transfected with siRNA targeting circRNA_0079586); 3. circRNA_RanGAP1 siRNA group (HUVEC cells transfected with siRNA targeting circRNA_RanGAP1); and 4. circRNA_0079586 + circRNA_RanGAP1 siRNA group (HUVEC cells transfected with siRNAs targeting both circRNA_0079586 and circRNA_RanGAP1). In cellular model IV, HUVEC cells were divided into 2 groups, i.e., 1. NC group (HUVEC cells transfected with NC); 2. miR-183-5p mimics group (HUVEC cells transfected with miR-183-5p mimics). In cellular model V, HUVEC cells were divided into 2 groups, i.e., 1. NC group (HUVEC cells transfected with NC); 2. miR-877-3p mimics group (HUVEC cells transfected with miR-877-3p mimics). All transfection was done using the Lipofectamine RNAiMAX transfection reagent (Invitrogen, Carlsbad, CA) according to the directions of the transfection reagent manufacturer. All transfected cells were harvested 48 h later for subsequent analyses.

Vector construction, mutagenesis and luciferase assay. Our sequence analysis showed that miR-183-5p could potentially target circRNA_0079586, so luciferase vectors containing wild type and mutant circRNA_0079586 were established and transfected into HUVEC cells with miR-183-5p to study the effect of miR-183-5p on circRNA_0079586 expression. Specifically, the prediction upon the interaction between circRNA_0079586 and miR-183-5p was accomplished by Circular RNA Interactome (https://circularinteractome.nia.nih.gov/index.html). In brief, the wild type circRNA_0079586 sequence containing the miR-183-5p binding site was cloned into a pcDNA vector (Promega, Madison, WI) to generate a wild type circRNA_0079586 vector. Then, site directed mutagenesis was generated in the miR-183-5p binding site of circRNA_0079586, and the mutant type circRNA_0079586 was cloned into a pcDNA vector to generate a mutant type circRNA_0079586 vector. Then, both wild type and mutant type circRNA_0079586 vectors were co-transfected into HUVEC cells with miR-183-5p using the Lipofectamine RNAiMAX transfection reagent according to the directions of the transfection reagent manufacturer, and the luciferase activity of transfected cells was assayed 48 h later using a Dual Luciferase Assay kit (Promega, Madison, WI) according to the directions of the assay kit manufacturer. Similarly, our sequence analysis by Circular
RNA Interactome showed that miR-877-3p could potentially target circRNA_RanGAP1, so luciferase vectors containing wild type and mutant circRNA_RanGAP1 were established and transfected into HUVEC cells with miR-877-3p to study the effect of miR-877-3p on circRNA_RanGAP1 expression using the methods described above. In addition, the prediction upon the interaction between miR-183-5p/miR-887-3p and MPO mRNA was accomplished by MirDB (www.mirdb.org). To study the effect of miR-877-3p and miR-183-5p on MPO expression, the wild type MPO promoter sequence containing the miR-183-5p or miR-877-3p binding site was cloned into pcDNA vectors, and site directed mutagenesis was generated in the miR-183-5p or miR-877-3p binding site of MPO, and the mutant type MPO sequence containing the mutated miR-183-5p or miR-877-3p binding site was also cloned into pcDNA vectors to generate mutant type MOP vectors. Then, both wild type and mutant type MPO vectors were co-transfected into HUVEC cells with miR-183-5p/miR-877-3p using the Lipofectamine RNAiMAX transfection reagent according to the directions of the transfection reagent manufacturer, and the luciferase activity of transfected cells was assayed 48 h later using a Dual Luciferase Assay kit.

Western blot analysis. Total protein was isolated from each sample by using a RIPA buffer (Sigma Aldrich, St. Louis, MO) according to the directions of the buffer manufacturer. Then, after 15 min of centrifugation at 13,400 g, the protein supernatant was quantified by using a BCA protein assay (Sigma Aldrich, St. Louis, MO) according to the directions of the assay kit manufacturer to determine protein concentration. In the next step, 10 µg of total protein from each sample was separated on a 10% SDS-PAGE gel and blotted onto a PVDF membrane (Roche, Indianapolis, IN), which was then blocked at room temperature for 2 h in a TBST buffer containing 5% goat milk, and then probed in sequence with primary anti-MPO monoclonal antibody and HRP-conjugated IgG secondary antibody (Santa Cruz Biotechnology, Dallas, TX) according to the incubation conditions suggested by the antibody manufacturer. Finally, the target protein bands were identified by using an enhanced chemiluminescence reagent (ECL) (Sigma Aldrich, St. Louis, MO) according to the directions of the reagent manufacturer.

Statistical analysis. All experiments were done ≥ 3 times. The results were ex-shown as mean ± SEM. Statistical analysis was done in SPSS 17.0 (SPSS, Chicago, IL) by utilizing the Student’s t-tests for inter-group comparisons. P < 0.05 was deemed statistically significant.

Results
Clinical features of the patients. We recruited IA (intracranial aneurysm) patients and divided them into two groups based on the status of IA: RIAS (ruptured intracranial aneurysms) and UIAS (unruptured intracranial aneurysms). Tissue samples were collected after surgery from patients in both groups. The clinical features including sex, age, hypertension, smoking history, lesion size were compared between the two groups. No obvious difference was found between patients in the two groups (Table 1).

Table 1. Basic clinical features of recruited patients.

| Characteristics | UIAs (N=16) | RIAS (N=18) | P value |
|-----------------|------------|-------------|---------|
| Sex, male       | 10 (62.5)  | 14 (77.8)   | 0.713   |
| Age, years      | 54.1 ± 5.9 | 53.5 ± 4.8  | 0.974   |
| Hypertension    |            |             | 0.368   |
| Yes             | 13 (81.3)  | 16 (83.3)   |         |
| No              | 3 (18.7)   | 2 (16.7)    |         |
| Smoke history   |            |             | 0.112   |
| Yes             | 9 (56.3)   | 9 (50.0)    |         |
| No              | 7 (43.7)   | 9 (50.0)    |         |
| Size, cm        | 2.1 ± 0.4  | 1.9 ± 0.3   | 0.846   |
| Multiple        |            |             | 0.259   |
| Yes             | 3 (18.7)   | 5 (27.8)    |         |
| No              | 13 (81.3)  | 13 (72.2)   |         |

Shear stress reshaped the expression of circRNAs in the endothelial cells of IA patients. Previous reports revealed that circRNAs played crucial roles in the pathogenesis of IA. We collected the endothelial cells from IA tissue samples and subjected them to microarray screening to examine the differentially expressed circRNAs between RIAS and UIAs. The expression of circRNA_0004543, circRNA_0079586, circRNA_0000231, circRNA_003204, circRNA_0454542, circRNA_0091822, circRNA_RanGAP1, circRNA_0943034 and circRNA_320434 was remarkably elevated in RIAS when compared with UIAs. On the contrary, the expression of circRNA_0003492, circRNA_0011032, circRNA_0004264, circRNA_0002331, circRNA_0004528 and circRNA_0000345 was notably suppressed in RIAS (Fig. 1A). Furthermore, we treated HUVECs with WSS (wall shear stress) and TF (turbulent flow), followed by circRNAs screening to find the differentially expressed circRNAs in HUVECs treated under the two conditions. The expression of circRNA_0008748, circRNA_0032813, circRNA_0000221, circRNA_0079586, circRNA_0091822, circRNA_RanGAP1, circRNA_0009011 and circRNA_00009321 was significantly enhanced in TF-treated HUVECs when compared with WSS-treated
The expression of circRNA_0009035, circRNA_0000732, circRNA_0009841, circRNA_0000948 and circRNA_0000322 was apparently repressed in TF-treated HUVECs when compared with WSS-treated HUVECs (Fig. 1B).

Luciferase assays revealed the regulatory relationship between circRNA_0079586/miR-183-5p, circRNA_RanGAP1/miR-877-3p, miR-183-5p/MPO, and miR-877-3p/MPO. Sequence analysis showed that miR-183-5p could potentially target circRNA-0079586, so luciferase vectors containing wild type and mutant circRNA-0079586 were established and transfected into HUVEC cells with miR-183-5p. The luciferase activity of wild type circRNA-0079586 was significantly suppressed by miR-183-5p, while the luciferase activity of mutant circRNA-0079586 remained unchanged when compared with the control (Fig. 2A). Sequence analysis showed that miR-877-3p could potentially target circRNA-RanGAP1, so luciferase vectors containing wild type and mutant circRNA-RanGAP1 were established and transfected into HUVEC cells with miR-877-3p. The luciferase activity of wild type circRNA-RanGAP1 was significantly suppressed by miR-877-3p, while the luciferase activity of mutant circRNA-RanGAP1 remained unchanged when compared with the control (Fig. 2B). Sequence analysis showed that miR-183-5p could potentially target MPO, so luciferase vectors containing wild type and mutant MPO were established and transfected into HUVEC cells with miR-183-5p. The luciferase activity of wild type MPO was significantly suppressed by miR-183-5p, while the luciferase activ-
The expression of mutant MPO remained unchanged when compared with the control (Fig. 2C). Sequence analysis showed that miR-877-3p could potentially target MPO, so luciferase vectors containing wild type and mutant MPO were established and transfected into HUVEC cells with miR-877-3p. The luciferase activity of wild type MPO was significantly suppressed by miR-877-3p, while the luciferase activity of mutant MPO remained unchanged when compared with the control (Fig. 2D). And to further verify the regulatory association between the miRNA and its possible target gene, we observed the relative expression of potential target genes in HUVEC cells overexpressing miR-183-5p or miR-887-3p. Accordingly, the relative expression of circRNA-0079586 was inhibited by the overexpression of miR-183-5p (*P value < 0.05 vs. NC group). (F) Relative expression of MPO mRNA was inhibited by the overexpression of miR-183-5p (*P value < 0.05 vs. NC group). (G) Relative expression of circRNA-RanGAP1 was inhibited by the overexpression of miR-887-3p (*P value < 0.05 vs. NC group). (H) Relative expression of MPO mRNA was inhibited by the overexpression of miR-887-3p (*P value < 0.05 vs. NC group).

Different expression of circRNA-0079586, circRNA-RanGAP1, miR-183-5p, miR-877-3p and MPO mRNA in the endothelial cells collected from UIAs and RIAs patients. Quantitative real time PCR was performed to analyze the expression of circRNA-0079586, circRNA-RanGAP1, miR-183-5p, miR-877-3p and MPO mRNA in the endothelial cells collected from UIAs and RIAs patients. The expression of circRNA-0079586 (Fig. 3A) and circRNA-RanGAP1 (Fig. 3B) was remarkably increased in endothelial cells from RIAs patients. The expression of miR-183-5p (Fig. 3C) and miR-877-3p (Fig. 3D) was notably decreased in endothelial cells from RIAs patients. The expression of MPO mRNA (Fig. 3E) was apparently increased in endothelial cells from RIAs patients.

Alteration of circRNA-0079586 and circRNA-RanGAP1 expression significantly changed the expression of miR-183-5p, miR-877-3p and MPO in TF-treated HUVECs. CircRNA-0079586 and circRNA-RanGAP1 siRNAs were transfected into TF-treated HUVECs to evaluate its effect on the expression of circRNA-0079586, circRNA-RanGAP1, miR-183-5p, miR-877-3p and MPO. The expression of circRNA-0079586 was dramatically suppressed in TF-treated HUVECs by circRNA-0079586 siRNA (Fig. 4A). The expression of circRNA-RanGAP1 was dramatically suppressed in TF-treated HUVECs by circRNA-0079586 siRNA (Fig. 4B). TF treatment remarkably down-regulated the expression of miR-183-5p and miR-877-3p when compared with WSS treatment. The expression of miR-183-5p was significantly activated in TF-treated HUVECs by circRNA-0079586 siRNA (Fig. 4C). The expression of miR-877-3p was significantly activated in TF-treated HUVECs by circRNA-0079586 siRNA (Fig. 4D). The expression of MPO mRNA and protein was notably up-regulated in TF-treated HUVECs when compared with WSS-treated HUVECs. CircRNA-0079586 and circRNA-RanGAP1 siRNAs obviously decreased the expression of MPO mRNA (Fig. 4E) and protein (Fig. 4F) in TF-treated HUVECs. In order to further explore the effect of circRNA-0079586 and circRNA-RanGAP1 expression on the expression of miR-183-5p, miR-877-3p and MPO, we overexpressed and repressed the expression of circRNA-0079586 and circRNA-RanGAP1 in HUVECs. The expression of circRNA-0079586 was dramatically enhanced in HUVECs.
transfected with p-circRNA-0079586 and p-circRNA_0079586 + p-circRNA_RanGAP1 (Fig. 5A). The expres-
sion of circRNA- RanGAP1 was dramatically enhanced in the endothelial cells collected from RIAs patients (*P < 0.05 vs. UIAs). (B) The expression of circRNA-RanGAP1 was enhanced in the endothelial cells collected from RIAs patients (*P < 0.05 vs. UIAs). (C) The expression of miR-183-5p was inhibited in the endothelial cells collected from RIAs patients (*P < 0.05 vs. UIAs). (D) The expression of miR-877-3p was inhibited in the endothelial cells collected from RIAs patients (*P < 0.05 vs. UIAs). (E) The expression of MPO mRNA was enhanced in the endothelial cells collected from RIAs patients (*P < 0.05 vs. UIAs).

Discussion
In this study, we recruited UIAs and RIAs patients and collected their tissue samples to compare the different expression of circRNAs using microarray screening. We found a batch of up-regulated and down-regulated circRNAs between RIAs and UIAs patients. In addition, we performed luciferase assay to explore the regulatory relationship between circRNAs and miRNAs, as well as between the miRNAs and their target genes. The luciferase activity of circRNA-0079586 was suppressed by miR-183-5p and the luciferase activity of circRNA-RanGAP1 was suppressed by miR-877-3p. The luciferase activity of MPO was inhibited by miR-183-5p and miR-877-3p.

High WSS values may be detected at possible locations of IA rupture as well as the neck section of IA lesions34,35. Also, experimental IA models with IA rupture induced by high WSS gradients showed that IA is extremely sensitive to the diseases of intracranial arteries induced by high WSS36,37. The effect of WSS on IA rupture remains unclear, although WSS with excessively reduced focal hemodynamics may lead to structural
fragility as well as reduced resistibility of the aneurysmal wall. A reduced magnitude of WSS can also enhance chronic inflammation as well as atherosclerotic changes induced by macrophages, which in turn cause the thinning of the aneurysmal wall to cause further rupture. In this study, we performed qPCR to compare the different expression of circRNA-0079586, circRNA-RanGAP1, miR-183-5p, miR-877-3p and MPO in the endothelial cells collected from UIAs and RIAs patients. The expression of circRNA-0079586 and circRNA-RanGAP1 was significantly enhanced in RIAs patients when compared with UIAs patients. The expression of miR-183-5p and miR-877-3p was remarkably repressed in RIAs patients when compared with UIAs patients. The expression of MPO was significantly activated in RIAs patients when compared with UIAs patients.

Wang et al. used high throughput sequencing to screen the effects of circRNAs on GM and paired non-cancer tissues. They found that circ_0079586 was up-regulated in GM specimens. Located at chr7: 23353140—23383472 and containing 586 base pairs, circ_0079586 is generated by the splicing of IGF2BP3. In this study, they used high throughput sequencing to screen the effects of circRNAs on GM and paired non-cancer tissues. They found that circ_0079586 was up-regulated in GM specimens. Located at chr7: 23353140—23383472 and containing 586 base pairs, circ_0079586 is generated by the splicing of IGF2BP3. In this study, they used high throughput sequencing to screen the effects of circRNAs on GM and paired non-cancer tissues. They found that circ_0079586 was up-regulated in GM specimens. Located at chr7: 23353140—23383472 and containing 586 base pairs, circ_0079586 is generated by the splicing of IGF2BP3.
Figure 5. Overexpression of circRNA_0079586 and circRNA-RanGAP1 suppressed the expression of miR-183-5p and miR-877-3p, respectively, and activated the expression of MPO in HUVECs. (A) The expression of circRNA_0079586 was dramatically enhanced in HUVECs transfected with p-circRNA_0079586 and p-circRNA_0079586 + p-circRNA_RanGAP1 (*P < 0.05 vs. NC). (B) The expression of circRNA-RanGAP1 was dramatically enhanced in HUVECs transfected with p-circRNA-RanGAP1 and p-circRNA_0079586 + p-circRNA_RanGAP1 (*P < 0.05 vs. NC). (C) The expression of miR-183-5p was obviously suppressed in HUVECs transfected with p-circRNA-0079586 and p-circRNA_0079586 + p-circRNA_RanGAP1 (*P < 0.05 vs. NC). (D) The expression of miR-877-3p was apparently suppressed in HUVECs transfected with p-circRNA_RanGAP1 and p-circRNA_0079586 + p-circRNA_RanGAP1 (*P < 0.05 vs. NC). (E) The expression of MPO mRNA was significantly increased in HUVECs transfected with p-circRNA-0079586 or p-circRNA_RanGAP1 alone, and to a higher extent in HUVECs transfected with p-circRNA_0079586 + p-circRNA_RanGAP1 (*P < 0.05 vs. NC; **P < 0.05 vs. p-circRNA_0079586). (F) The expression of MPO protein was significantly increased in HUVECs transfected with p-circRNA-0079586 or p-circRNA_RanGAP1 alone, and to a higher extent in HUVECs transfected with p-circRNA_0079586 + p-circRNA_RanGAP1 (*P < 0.05 vs. NC; **P < 0.05 vs. p-circRNA_0079586).
Figure 6. Suppression of circRNA_0079586 and circRNA-RanGAP1 enhanced the expression of miR-183-5p and miR-877-3p, respectively, and repressed the expression of MPO in HUVECs. (A) The expression of circRNA-0079586 was dramatically suppressed in HUVECs transfected with circRNA_0079586 siRNA and circRNA_0079586 siRNA + circRNA_RanGAP1 siRNA (*P < 0.05 vs. NC siRNA). (B) The expression of circRNA-RanGAP1 was dramatically repressed in HUVECs transfected with circRNA_RanGAP1 siRNA and circRNA_0079586 siRNA + circRNA_RanGAP1 siRNA (*P < 0.05 vs. NC siRNA). (C) The expression of miR-183-5p was obviously activated in HUVECs transfected with circRNA_0079586 siRNA and circRNA_0079586 siRNA + circRNA_RanGAP1 siRNA (*P < 0.05 vs. NC siRNA). (D) The expression of miR-877-3p was apparently enhanced in HUVECs transfected with circRNA_RanGAP1 siRNA and circRNA_0079586 siRNA + circRNA_RanGAP1 siRNA (*P < 0.05 vs. NC siRNA). (E) The expression of MPO mRNA was significantly inhibited in HUVECs transfected with circRNA_0079586 siRNA or circRNA_RanGAP1 siRNA alone, and to a higher extent in HUVECs transfected with circRNA_0079586 siRNA + circRNA_RanGAP1 siRNA (*P < 0.05 vs. NC siRNA; **P < 0.05 vs. circRNA_0079586 siRNA). (F) The expression of MPO protein was significantly inhibited in HUVECs transfected with circRNA_0079586 siRNA or circRNA_RanGAP1 siRNA alone, and to a higher extent in HUVECs transfected with circRNA_0079586 siRNA + circRNA_RanGAP1 siRNA (*P < 0.05 vs. NC siRNA; **P < 0.05 vs. circRNA_0079586 siRNA).
we altered the expression of circRNA-0079586 and circRNA-RanGAP1 in HUVECs. The expression of circRNA-0079586 and circRNA-RanGAP1 was negatively correlated with the expression of miR-183-5p and miR-877-3p, respectively, but positively correlated with the expression of MPO mRNA and protein. Located on chromosome 7, miR-183 has been shown to play a role as prospective oncogene in lung cancer, prostate cancer, breast cancer, colorectal cancer as well as hepatocellular cancer. In general, miR-183-5p is either abnormally upregulated or downregulated in different types of cancers. As an example, miR-183-5p is upregulated in hepatocellular cancer to inhibit cancer cell apoptosis by suppressing PDCD4 expression. However, miR-183-5p also inhibited the invasion of gastric cancer by targeting Ezrin. In one study, circ-RanGAP1 expression was found to be considerably upregulated in GC tissues, especially in the later stage of GC. MiR-877-3p was shown to promote the differentiation and proliferation of lung and bladder cancer cells. Also, miR-877-3p was shown to inhibit the differentiation of mesenchymal stem cells in the lungs to myofibroblasts to alleviate lung fibrosis caused by bleomycin. It was also suggested that circ-RanGAP1 can promote the invasion and metastasis of GC by sponging the expression of miR-877-3p, a tumor suppressor. Another research signified that miR-877 might serve as a tumor suppressor to block the expansion of hepatocellular carcinoma cells.

In the presence of H2O2, MPO is generated by neutrophilic respiratory burst to promote the production of chlorinating agents such as hypochlorous acid. Besides its prominent role in protection against microbes, MPO has also been implicated in the destabilization of atherosclerotic plaques. It was actually found that a short treatment using a low dose of Ox-LDL noticeably boosted the number EC-binding monocytes as well as the expression of ICAM-1 on the surface of EC cells. Furthermore, a prolonged treatment using a high dose of Ox-LDL caused increased cytoxicity as well as EC monolayer detachment, indicating that Ox-LDL stimulation may lead to atherosclerosis by promoting the expression of adhesion molecules on EC surface. In cerebral aneurysm patients, the concentrations of circulating MPO are locally increased in CA sacs to enhance the number of MPO-positive cells such as neutrophils in the aneurysm. In a CA mouse model, the deficiency of MPO reduced the levels of pro-inflammatory molecules in cerebral arteries while lowering the number of leukocytes to alleviate the rupture of cerebral aneurysm. Since MPO shortage is commonly seen in human populations, it is important to analyze the rate of cerebral aneurysm in MPO deficiency. In UIA patients, MPO showed the association with the danger of aneurysm rupture, indicating that MPO may be used as a potential biomarker for aneurysm rupture.

**Conclusion**

In this study, we established two MPO-modulating signaling pathways of circRNA_0079586/miR-183-5p/MPO and circRNA_RanGAP1/miR-877-3p/MPO. These two signaling pathways are involved in the pathogenesis of intracranial aneurysms rupture. In patients with ruptured intracranial aneurysms, the expression of MPO was up-regulated with promoted expression of circRNA_0079586 and circRNA_RanGAP1.

**Data availability**

The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request.

Received: 7 April 2021; Accepted: 30 June 2021
Published online: 05 October 2021

**References**

1. Teunissen, L. L., Rinkel, G. J., Algra, A. & van Gijn, J. Risk factors for subarachnoid hemorrhage: A systematic review. *Stroke* **27**, 544–549 (1996).
2. Vlak, M. H., Rinkel, G. J., Greebe, P., van der Bom, J. G. & Algra, A. Trigger factors and their attributable risk for rupture of intracranial aneurysms: A case-crossover study. *Stroke* **42**, 1878–1882 (2011).
3. Rinkel, G. J., Djibuti, M., Algra, A. & van Gijn, J. Prevalence and risk of rupture of intracranial aneurysms: a systematic review. *Stroke* **29**, 251–256 (1998).
4. de Rooij, N. K., Linn, F. H., van der Plas, J. A., Algra, A. & Rinkel, G. J. Incidence of subarachnoid haemorrhage: A systematic review with emphasis on region, age, gender and time trends. *J. Neurol. Neurosurg. Psychiatry* **78**, 1365–1372 (2007).
5. Phillips, L. H. 2nd., Whisnant, J. P., O’Fallon, W. M. & Sundt, T. M. The unchanging pattern of subarachnoid hemorrhage in a community. *Neurology* **30**, 1034–1040 (1980).
6. Lawson, M. F., Chi, Y. Y., Velat, G. J., Mocco, J. D. & Hoh, B. L. Timing of aneurysm surgery: The international cooperative study revisited in the era of endovascular coiling. *J. Neurointerv. Surg.* **2**, 131–134 (2010).
7. Baharoglu, M. I., Schirmer, C. M., Hoit, D. A., Gao, B. L. & Malek, A. M. Aneurysm inflow-angle as a discriminant for rupture in sidewall cerebral aneurysms: Morphometric and computational fluid dynamic analysis. *Stroke* **41**, 1423–1430 (2010).
8. Xiang, J. et al. Hemodynamic-morphologic discriminants for intracranial aneurysm rupture. *Stroke* **42**, 144–152 (2011).
9. Miyazaki, Y. et al. High shear stress can initiate both platelet aggregation and shedding of procoagulant containing microparticles. *Blood* **88**, 3456–3464 (1996).
10. Neshbit, W. S. et al. A shear gradient-dependent platelet aggregation mechanism drives thrombus formation. *Nat. Med.* **15**, 665–673 (2009).
11. Tovar-Lopez, F. J. et al. A microfluidics device to monitor platelet aggregation dynamics in response to strain rate micro-gradients in flowing blood. *Lab Chip* **10**, 291–302 (2010).
12. Kundu, S. K. et al. Description of an in vitro platelet function analyzer—PFA-100. *Semin. Thromb. Hemost.* **21**(Suppl 2), 106–112 (1995).
13. McGlasson, D. L. & Fritsma, G. A. Whole blood platelet aggregometry and platelet function testing. *Semin. Thromb. Hemost.* **35**, 168–180 (2009).
14. Fisher, A. B., Chien, S., Barakat, A. I. & Nerem, R. M. Endothelial cellular response to altered shear stress. *Am. J. Physiol. Lung Cell Mol. Physiol.* **281**, L529–L533 (2001).
15. Meng, H. et al. Progressive aneurysm development following hemodynamic insult. *J. Neurosurg.* **114**, 1095–1103 (2011).
16. Yao, T., Chen, Q., Fu, L. & Guo, J. Circular RNAs: Biogenesis, properties, roles, and their relationships with liver diseases. *Hepatol. Res.* **47**, 497–504 (2017).
17. Yao, C. & Yu, B. Role of long noncoding RNAs and circular RNAs in nerve regeneration. Front. Mol. Neurosci. 12, 165 (2019).
18. Vicenz, Q. & Westhol, E. Biogenesis of circular RNAs. Cell 159(1), 13–14. https://doi.org/10.1016/j.cell.2014.09.005 (2014).
19. Hou, L. D. & Zhang, J. Circular RNAs: An emerging type of RNA in cancer. Int. J. Immunopathol. Pharmacol. 30, 1–6 (2017).
20. Peng, L., Yuan, X. Q. & Li, G. C. The emerging landscape of circular RNA cIR5 in cancer (review). Oncol. Rep. 33, 2669–2674 (2015).
21. Greving, J. P. et al. Development of the PHASES score for prediction of risk of rupture of intracranial aneurysms: A pooled analysis of six prospective cohort studies. Lancet Neurol. 13, 59–66 (2014).
22. Chu, Y. et al. Myeloperoxidase is increased in human cerebral aneurysms and increases formation and rupture of cerebral aneurysms in mice. Stroke 46, 1651–1658 (2015).
23. DeLeo, M. J. 3rd. et al. Carotid artery brain aneurysm model: in vivo molecular enzyme-specific MR imaging of active inflammation in a pilot study. Radiology 252, 696–703 (2009).
24. Guo, X., Tan, W. & Wang, C. The emerging roles of exosomal circRNAs in diseases. Clin. Transl. Oncol. 23(6), 1020–1033 (2021).
25. Wang, Y. et al. miR-183-5p alleviates early injury after intracerebral hemorrhage by inhibiting heme oxygenase-1 expression. Aging (Albany NY) 12(13), 12869–12895 (2020).
26. Goodwin, A. J. et al. Circulating miRNA 887 is differentially expressed in ARDS and modulates endothelial function. Am. J. Physiol. Lung Cell. Mol. Physiol. 318(6), L1261–L1269 (2020).
27. Li, C. Y. Ma, L. & Yu, B. Circular RNA hsa_circ_0003575 regulates oxLDL induced vascular endothelial cells proliferation and angiogenesis. Biomed. Pharmacother. 95, 1514–1519 (2017).
28. Dang, R. Y. Liu, F. L. & Li, Y. Circular RNA hsa_circ_0010729 regulates vascular endothelial cell proliferation and apoptosis by targeting the miR-186/HIF-1alpha axis. Biochem. Biophys. Res. Commun. 490, 104–110 (2017).
29. Chen, J. et al. Elevation in the expression of circ_007986 predicts poor prognosis and accelerating progression in glioma via interactions with the miR-183-5p/MDM4 signaling pathway. Oncol. Targets Ther. 13, 5135–5143 (2020).
30. Li, H. et al. Comparison between smaller ruptured intracranial aneurysm and larger un-ruptured intracranial aneurysm: Gene expression profile analysis. Neurosurg. Rev. 40, 419–425 (2017).
31. Ollikainen, E. et al. Myeloperoxidase associates with degenerative remodeling and rupture of the saccular intracranial aneurysm wall. J. Neuropathol. Exp. Neurol. 77, 461–488 (2018).
32. Boscolo, E. et al. Endothelial cells from human cerebral aneurysm and arteriovenous malformation release ET-1 in response to vessel rupture. Int. J. Mol. Med. 18(S), 813–819 (2006).
33. Hao, Q. et al. Procedure for the isolation of endothelial cells from human cerebral arteriovenous malformation (cAVM) tissues. Front. Cell. Neurosci. 12, 30 (2018).
34. Kulcsar, Z. et al. Hemodynamics of cerebral aneurysm initiation: The role of wall shear stress and spatial wall shear stress gradient. AJNR Am. J. Neuroradiol. 32, 587–594 (2011).
35. Shojima, M. et al. Magnitude and role of wall shear stress on cerebral aneurysm: Computational fluid dynamic study of 20 middle cerebral artery aneurysms. Stroke 35, 2500–2505 (2004).
36. Cebral, J. et al. Flow conditions in the intracranial aneurysm lumen are associated with inflammation and degenerative changes of the aneurysm Wall. AJNR Am. J. Neuroradiol. 38, 119–126 (2017).
37. Meng, H. et al. Complex hemodynamics at the apex of an arterial bifurcation induces vascular remodeling resembling cerebral aneurysm initiation. Stroke 38, 1924–1931 (2007).
38. Kadirvel, R. et al. The influence of hemodynamic forces on biomarkers in the walls of elastase-induced aneurysms in rabbits. Neuroradiology 49, 1041–1053 (2007).
39. Nixon, A. M., Gunel, M. & Sumpio, B. E. The critical role of hemodynamics in the development of cerebral vascular disease. J. Neurosurg. 112, 1240–1253 (2010).
40. Wang, R. et al. EIF4A3-induced circular RNA MMP9 (circMMP9) acts as a sponge of miR-124 and promotes glioblastoma multiformal cell tumorigenesis. Mol. Cancer 17, 166 (2018).
41. Schafer, A. et al. Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma. Int. J. Cancer 126, 1166–1176 (2010).
42. Zhang, L., Quan, H., Wang, S., Li, X. & Che, X. MiR-183 promotes growth of non-small cell lung cancer cells through FoxO1 inhibition. Tumour Biol. 36, 8121–8126 (2015).
43. Li, J. et al. miR-183 inhibits TGF-beta1-induced apoptosis by downregulation of PDCD4 expression in human hepatocellular carcinoma cells. BMC Cancer 10, 354 (2010).
44. Cao, L. L. et al. miR-183 inhibits invasion of gastric cancer by targeting Erzin. Int. J. Clin. Exp. Pathol. 7, 5582–5594 (2014).
45. Lu, J. et al. Circular RNA circ-RanGAP1 regulates VEGFA expression by targeting miR-877-3p to facilitate gastric cancer invasion and metastasis. Cancer Lett. 471, 38–48 (2020).
46. Wang, C. et al. miR-877-3p targets Smad7 and is associated with myofibroblast differentiation and bleomycin-induced lung fibrosis. Sci. Rep. 6, 30122 (2016).
47. Li, S. et al. Up-regulation of p16 by miR-877-3p inhibits proliferation of bladder cancer. Oncotarget 7, 51773–51783 (2016).
48. Huang, X., Qin, J. & Lu, S. Up-regulation of miR-877 induced by paclitaxel inhibits hepatocellular carcinoma cell proliferation through targeting FOXM1. Int. J. Clin. Exp. Pathol. 8, 1513–1524 (2015).
49. Nicholls, S. J. & Hazen, S. L. Myeloperoxidase and cardiovascular disease. Arterioscler. Thromb. Vasc. Biol. 25, 1102–1111 (2005).
50. Nauseef, W. M., Root, R. K. & Malech, H. L. Biochemical and immunologic analysis of hereditary myeloperoxidase deficiency. J. Clin. Pathol. 71, 1297–1307 (1983).
51. Gounis, M. J. et al. Myeloperoxidase in human intracranial aneurysms: Preliminary evidence. Stroke 45, 1474–1477 (2014).

Acknowledgements
This work was supported by Liaoning natural science funding 2018 (No. 20180550818) and Liaoning educational department youth funding (No. JYTQN201736).

Author contributions
D.X. and Z.Z. planned the study, R.S. and L.G. collected and analyzed the data, Z.Z. finished the manuscript; D.X. read and approved the final manuscript.

Competing interests
The authors declare no competing interests.

Additional information
Supplementary Information The online version contains supplementary material available at https://doi.org/10.1038/s41598-021-99062-w.

12
Scientific Reports | (2021) 11:19800 | https://doi.org/10.1038/s41598-021-99062-w
